Study ID: PCORI KIDCARE Rare Disease Kawasaki comparative effectiveness
PCORI Rare Disease comparative effectiveness clinical trial to compare 2nd IVIG vs. infliximab for patients with IVIG resistance
KIDCARE is a 3-year (2.75-years of enrollment), Phase III, two-arm, randomized, multi-center, treatment study. The goal of this study is to compare infliximab to a second intravenous immunoglobulin (IVIG) infusion for treatment of persistent or recrudescent fever in children with KD who fail to become afebrile after the first IVIG infusion.
Sioux Falls Region
Archana Chatterjee, MD, PhD
Active - Open to Accrual
For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.